Recombinant hepatitis B vaccine Immunogenicity in presence of hepatitis C virus seropositivity

Kamel, Moemena

doi:10.1016/s0140-6736(94)91510-5

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have compared the immunogenicity of hepatitis B vaccination with different protocols between healthy individuals and hepatitis C patients. Some of them, like our study, have failed to demonstrate a significant correlation between chronic hepatitis C and antibody response [22,[26][27][28] . However, some authors have shown that responses were weaker in patients than in controls [23,24,29,30] .…”

Section: Discussioncontrasting

confidence: 63%

Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

Daryani

Nassiri-Toosi

Rashidi

et al. 2007

WJG

View full text Add to dashboard Cite

Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection:A case-control study. World J Gastroenterol 2007; 13(2): 294-298http://www.wjgnet.com/1007-9327/13/294.asp INTRODUCTIONOne major transmission route for both hepatitis C virus (HCV) and hepatitis B virus (HBV) is the parenteral route, and the sources of infection include administration of blood or blood products [1,2] , intravenous drug use [3,4] and needle-stick accidents [5,6] . According to the analysis of the Third National Health and Nutrition Survey, more than 25% of HCV-positive patients in the United States had hepatitis B markers, a proportion nearly six times that in the HCV-negative group [3] . However, the actual prevalence of HBV infection in patients with HCV infection is probably underestimated [7,8] . Although it has been shown that superinfection of either HBV or HCV may suppress the other's replicative levels, coinfection with both viruses has synergistic effects with regard to histological lesions, progression to cirrhosis and cancer development [9][10][11][12][13] . As such it has been recommended by the National Institutes of Health (NIH) that individuals with HCV be vaccinated against HBV infection to prevent such an outcome [14] . HBV vaccination at standard doses (20 µg for adults at mo 0, 1, and 6) results in an effective antibody response in 90% to 98% of healthy individuals [15,16] . However, reduced immunog enicity of the vaccine has been established in persons with chronic liver disease, patients receiving hemodialysis, patients with HIV infection and those awaiting transplantation [17][18][19][20][21] . To the best of our knowledge, only a few studies, with inconsistent results, have compared the immunogenicity of standard HBV vaccination in chronic hepatitis C patients with that in healthy individuals through a case-control study [22][23][24] . Therefore, we found it valuable to compare the response of standard HBV vaccination between patients with chronic HCV infection and healthy individuals in a prospective case-control study. METHODS: This is a prospective case-control study. A total of 38 patients with chronic HCV infection and 40 healthy controls were included. Vaccination was performed by injection of 20 µg recombinant HBsAg into the deltoid muscle at mo 0, 1 and 6. Anti-HBs concentration was determined 3 mo after the last dose and compared between the two groups. The response pattern was characterized as (1) high-response when the anti-HBs antibody titer was > 100 IU/L, (2) low-response when the titer was 10-100 IU/L and (3) no-response when the titer was < 10 IU/L. MATERIALS AND METHODS Subjects RESULTS:In the patient group, there were 10/38 (26.3%) non-responders, 8/38 (21.1%) low-responders and 20/38 (52.6%) high-responders. The corresponding va l u e s i n t h e c o n t r o l g r o u p w e r e 2 / 4 0 ( 5 . 0 % ) , 7/40 (17.5%) and 31/40 (77.5%), respectively. The response pattern was statistically different between the two groups. In multivar...

show abstract

Section: Discussioncontrasting

confidence: 63%

Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

Daryani

Nassiri-Toosi

Rashidi

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…That is partially in contrast with other groups who used plasma-derived vaccine [29][30][31][32][33][34], Furthermore, responder vaccinees showed a length of time on HD slightly longer than non-responders: that is in keeping with the study of Steketee et al [35], Patients who survive on HD for longer periods are generally healthier and may be better able to develop an antibody response. Thus, subjects who have been on HD for a prolonged time should not be excluded from vaccination against hepatitis B. Immunogenicity to Engerix-B was not affected by the presence of anti-HCV, in contrast with other authors [36]: such a finding is a potential cost saving in an area where HCV prevalence is high. Moreover, screening patients for HCV antibodies is not recommended before vaccination.…”

Section: Discussionmentioning

confidence: 62%

Recombinant Hepatitis B Vaccine Use in Chronic Hemodialysis Patients

Fabrizi

Filippo

Marcelli

et al. 1996

Nephron

View full text Add to dashboard Cite

The prevalence of hepatitis B virus (HBV) infection in our unit was 45% (86/190): there were 77 (40.5%) and 9 (4.7%) patients with previous and persistent HBV infection, respectively. Recombinant hepatitis B vaccine was given to 118 chronic HD patients with a regimen of 3 double doses administered intramuscularly at 0, 1 and 2 months, obtaining a seroprotection rate of 67% (79/118), 57% (45/79) being high responders. At month 24, 78% (40/51) maintained protective levels of anti-HBs, 45% (18/40) of them being high responders. There was a statistically significant difference between responder and non-responder patients with regard to nutritional parameters such as serum total proteins and mean levels of transferrinemia. The number of diabetic patients was significantly increased in the nonresponder group. Patients with persistent antibodies (‘persistent responders’) were younger and had a shorter duration of HD treatment compared to those responders who rapidly lost anti-HBs (‘transient responders’). Serological positivity for antibodies against hepatitis B core antigen significantly facilitates the decrease of anti-HBs antibodies over time. We detected seven episodes of HBV infection among HD patients at our unit before the beginning of the vaccination program. On the contrary, there were no episodes of HBV infection among responder vaccinees during the 24-month follow-up period. After the initial cost of vaccination, a savings of US$ 3,272 per year was realized by the elimination of frequent serologic screening of vaccine responders.

show abstract

“…The controlled study of Cheng et al [1997] found the same immune response to hepatitis B vaccine in hemodialysis patients who were either anti-HCV positive or negative. Kamel et al [1994] also reported that HCV infection would not affect the immunogenicity of hepatitis B vaccine in healthy subjects. Our present controlled study disclosed similar anti-HBs response rates between chronic hepatitis C patients (group I) and healthy subjects (group II) on standard schedule of hepatitis B vaccination.…”

Section: Discussionmentioning

confidence: 98%

Hepatitis B vaccination in patients with chronic hepatitis C

Lee

Chan

et al. 1999

J. Med. Virol.

View full text Add to dashboard Cite

The aim of the study was to evaluate the safety, immunogenicity, and possible therapeutic effect of hepatitis B vaccine in patients with chronic hepatitis C. The subjects studied included three groups: group I, 26 patients with chronic hepatitis C who were susceptible to hepatitis B virus infection; group II, 35 healthy subjects who were susceptible to both hepatitis B and hepatitis C virus infection; and group III, 30 patients with chronic hepatitis C receiving no hepatitis B vaccination as controls. Three 20 microg/dose of recombinant hepatitis B vaccines were given to subjects of groups I and II in months 0, 1, and 6. Blood samples from the subjects were collected before and 1 month after each dose of vaccination for serological testing. The subjects of groups I and II had similar antibody to hepatitis B surface antigen (anti-HBs) response rates after the first (30.8% vs. 17.1%), second (61.5% vs. 60.0%), and third (88.5% vs. 91.4%) doses of vaccination. Also, their geometric mean titers of anti-HBs did not differ much when vaccination completed in 7 months (360 vs. 581 mIU/ml). During vaccination period, patients with chronic hepatitis C demonstrated no significant change of serum cytokines and HCV RNA levels, but significantly lowered ALT levels after three doses of vaccination. Hepatitis B vaccination is safe and immunogenic in patients with chronic hepatitis C. It did not significantly affect their levels of HCV RNA, but tended to lower ALT levels.

show abstract

Recombinant hepatitis B vaccine Immunogenicity in presence of hepatitis C virus seropositivity

Cited by 12 publications

References 0 publications

Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: A case-control study

Recombinant Hepatitis B Vaccine Use in Chronic Hemodialysis Patients

Hepatitis B vaccination in patients with chronic hepatitis C

Contact Info

Product

Resources

About